Company intelligence / Profile preview

Genostics

China

Ownership: Private
Development stage: Other

Overview

Genostics was a Chinese biotech company that partnered with Oncimmune to develop and commercialize the EarlyCDT technology—a blood-based autoantibody diagnostic for lung cancer detection. However, the partnership ended, with Oncimmune regaining rights to EarlyCDT in China, and there is no public information on Genostics' current internal pipeline or activity[1].

Therapeutic areas: Oncology
Modalities: Autoantibody-based diagnosticImmunodiagnostic
Industry: Protein Biomarker Diagnostics

Partnerships

Oncimmune (Licensing and development partnership for EarlyCDT in China, status: Terminated)

Beyond the preview

Go deeper on Genostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genostics.

Explore the full profile